RPL17 and breast carcinoma: Further research into the interplay between ANXA1 and MHC‐II in breast cancer could elucidate new strategies to counteract the adaptive resistance mechanisms employed by tumors, potentially leading to more effective combination therapies that prevent the upregulation of immune‐inhibitory molecules like ANXA1 in response to PD‐1/PD‐L1 blockade.